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Vaccines are efficacious, effective and safe measures 
to control COVID-19. Despite phase 3 and 4 studies, 
some concerns should be addressed in certain 
populations regarding its specific vaccine safety. One of 
them is the safety of the elderly. The majority of 
enrollees in clinical studies on COVID-19 vaccines have 
been young to middle-aged individuals, with few 
exceptions [1].  
For example, the median ages of enrollees in the two 
clinical trials using the mRNA vaccines are 51.4 and 52.0 
years [2,3]. Then, it is challenging to discuss the safety 
of these vaccines in the elderly based on the results of 
these clinical studies, then also needing real-world 
observations outside them and effectiveness 
assessments. 
In Japan, the eldest country globally, vaccination 
using the BNT162b2 mRNA COVID-19 vaccine began 
in February 2021 for healthcare workers, and in April 
2021, for the elderly. In this country, as in most places, 
when serious adverse events occur after vaccination, 
physicians are obligated to report them to Japan's 
Ministry of Health, Labour and Welfare (MHLW), 
which promptly discloses information on them publicly.  
Then, we reviewed the clinical features of 
individuals who died closely after vaccination using the 
database published by MHLW.  
A total of 9,783,387 doses of the vaccine were 
administered in Japan from February 17 to June 18, 2021. 
As of June 23, only 355 deaths have been reported, 
representing 3.63 deaths per 100,000 doses. Of those 355 
fatalities, 322 (90.7%) occurred in people older than 65, 
but 278 (78.3%) had underlying diseases. As of June 13, 
2021, causes of death have been published in 277 of the 
355 cases, including heart failure (n=37), hemorrhagic 
stroke (n=30) and cardiopulmonary diseases (n=30). 
According to the Ministry of Health, a causal relationship 
between death and vaccination was only suspected in 26 
(7.3%). Such a relationship was ruled out in 39, 
remaining unknown in 290 cases. 
Most of the deaths occurred within a week of 
vaccination (n=254, 71.5%) (Figure 1), especially on the 
second (n=72, 20.3%) and third day (n=49, 13.8%). 
Although the possibility of reporting bias cannot be 
denied, some deaths among elderly Japanese people after 
vaccination were also reported during the 2009 H1N1 
pandemic [4].   
Furthermore, the number of deaths might not have 
peaked immediately after vaccination if vaccination had 
not been associated with their deaths.  
There are several possibilities as to why many 
elderly people in Japan have died after vaccination. 
Besides the elderly have low organ reserves, they might 
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have been "overdosed" with the vaccine. Compared to 
Caucasians, Asians weigh approximately 20% less than 
them [5]. Despite that, the vaccine dose used in Japan and 
Western countries is the same, 30 μg. In phase 1 clinical 
trial of the vaccine, 10, 20, and 30 μg doses were 
administered, and a dose-dependent relationship was 
observed in adverse reactions [6]. Fever was observed in 
0% in the 10 and 20 microgram groups, but 8% in the 30 
μg group after the second dose, in those aged 65 to 85 
years.  
 
Figure 1. Number of deaths within the seven days following 
BNT162b2 mRNA COVID-19 vaccination. 
 
   
Although this would be considered a superficial and 
preliminary analysis with many broad conclusions, 
suppositions and speculations ,which could be 
controversial, our call is directed to raise the awareness 
on the constant need of the enhanced assessment of 
vaccine safety, which requires detailed and careful 
analysis by experts in the field, when occur. 
These findings led us to consider that acute 
inflammatory reactions may be associated with the 
vaccine, exacerbating underlying diseases, increasing the 
possibility of fatal complications. Although these data 
may suggest that deaths were related to the vaccine due 
to the time relationship, also the findings would be 
explained by the expected death rate in the population. 
Therefore, further studies are needed to improve the 
safety of vaccine administration in the elderly. Especially 
more safety studies on the elderly, as well as enhanced 
and careful pharmacovigilance of vaccinated population, 
is deserved [7], particularly in the context where 
COVID-19 vaccination is needed in the highest possible 
proportion of the world population to achieve efficient 
control of the pandemic, together with already fully 
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